Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Sopharma AD

Business and Financial Review • Mar 20, 2024

2543_rns_2024-03-20_b01f90ac-13be-4096-9cab-5d624aa74c7c.pdf

Business and Financial Review

Open in Viewer

Opens in native device viewer

Current report № 19/ 2024 Dated March 20, 2024

NOTIFICATION

"Sopharma" AD (the Company) notifies that for February 2024 the Company recorded an decrease in sales of 29% compared to the same month of the previous year, incl. 9% decrease in domestic sales and 43% decrease in export sales. From the beginning of 2024, the Company recorded a decrease in sales of 3%, incl. 2% growth in domestic sales and 7% decrease in export sales.

Ognian Donev

More from Sopharma AD

Regulatory Filings 2025
Dec 22
Regulatory Filings 2025
Dec 22
Director's Dealing 2025
Dec 22
Transaction in Own Shares 2025
Dec 22
Director's Dealing 2025
Dec 19
Capital/Financing Update 2025
Dec 19
Transaction in Own Shares 2025
Dec 18
Transaction in Own Shares 2025
Dec 17
Transaction in Own Shares 2025
Dec 16
Transaction in Own Shares 2025
Dec 15
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.